Collins has held senior executive roles at a number of early stage diagnostic and life science companies including Vysis Europe (Abbott Molecular Diagnostics), Quantase (Bio-Rad Laboratories), Gentronix, Biogenex and Pronostics.
Prior to DxS, Jeff Devlin held positions as executive vice president and executive committee member of Shire Pharmaceuticals, where he played a key role in strategy and integration. Before this he was a Partner in Ernst and Young’s life science division.
Dr. Stephen Little, chief executive officer of DxS, said: “We are delighted to be able to promote Jeff and Peter to more senior positions within the company. Both have contributed significantly to our vision of becoming one of the leaders in the personalised medicine space.”
